Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02709096 · ClinicalTrials.gov registry record · Phase 2
BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes
A Phase 2 study, sponsored by BioPharmX.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02709096 is a Phase 2 study that has completed, run by BioPharmX. The registered enrollment target is 33 participants.
The verdict
NCT02709096, a Phase 2 study, has completed, sponsored by BioPharmX.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate the comparative reduction of Propionibacterium acnes in-vivo following once daily topical administration of BPX-01 Minocycline 1% Topical Gel (BPX-01) or BPX-01 Vehicle control.
Interventions
- DRUG BPX-01, 1% Topical Gel
- DRUG BPX-01 Vehicle Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02709096
The ClinicalTrials.gov registry entry for NCT02709096 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioPharmX, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BPX-01, 1% Topical Gel is the first listed.
NCT02709096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02709096 about?
NCT02709096 is a clinical study titled "BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes". This is a Phase 2a study which is being conducted in healthy volunteers in order to evaluate the comparative reduction of Propionibacterium acnes in-vivo following once daily topical administration of BPX-01 Minocycline 1% Topical Gel (BPX-01) or BPX-01 Vehicle control.
What is the current status of trial NCT02709096?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2016-04. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02709096?
The interventions under investigation include: BPX-01, 1% Topical Gel (DRUG), BPX-01 Vehicle Gel (DRUG).
Who is sponsoring clinical trial NCT02709096?
This trial is sponsored by BioPharmX, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.